Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2022 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement...
March 21, 2022 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE)...
March 14, 2022 16:20 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue imsidolimab clinical development in...
March 07, 2022 08:50 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in...
January 05, 2022 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
November 29, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
November 15, 2021 19:24 ET | Source: AnaptysBio, Inc.

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
November 15, 2021 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohortsRobust pharmacokinetic...
November 04, 2021 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meetingTop-line data from ongoing imsidolimab ACORN...
October 25, 2021 16:37 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below...